Detection of B-RAF and N-RAS mutations in human melanoma.
about
Regulation of the expression and activity of the antiangiogenic homeobox gene GAX/MEOX2 by ZEB2 and microRNA-221Rewired ERK-JNK signaling pathways in melanomaFrequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frameThe ginsenoside 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol induces autophagy and apoptosis in human melanoma via AMPK/JNK phosphorylationFrequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanomaA phase 0 trial of riluzole in patients with resectable stage III and IV melanomaMEOX2 regulates nuclear factor-kappaB activity in vascular endothelial cells through interactions with p65 and IkappaBbetaSildenafil use and increased risk of incident melanoma in US men: a prospective cohort studyAssociation between BRAFV600E and NRASQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma.Clinical correlates of NRAS and BRAF mutations in primary human melanoma.Association of activated c-Met with NRAS-mutated human melanomas.Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway.Delving into somatic variation in sporadic melanoma.Mutational status of naevus-associated melanomas.Point mutations of protein kinases and individualised cancer therapy.Direct targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth.A novel AKT3 mutation in melanoma tumours and cell linesThe T1799A point mutation is present in posterior uveal melanomaThe metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4Expression of Phosphatase and Tensin Homologue, phospho-Akt, and p53 in Acral Benign and Malignant Melanocytic Neoplasms (Benign Nevi, Dysplastic Nevi, and Acral Melanomas)NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma.Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progressionChanges in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.Biological challenges of BRAF inhibitor therapySelumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion.The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes.What makes oncogenes mutually exclusive?Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.Selumetinib for the treatment of cancer.Pathology of Melanoma
P2860
Q24596485-F7763FB0-ECB0-498D-846B-13846B20553CQ24683737-FFBEAFAF-B864-48A3-A396-8F612644076EQ27851617-0D66B21B-29EA-42B4-90D3-AEBAC4B3BAFFQ28483092-4C804213-AC2A-4341-A64E-316FFE464776Q28542379-F6D7AC11-8A07-44C4-978E-BB010AD50966Q33387548-E7FE509E-4364-4415-964E-F11D327CABA7Q33616544-FA8FA97B-039E-4338-8281-5D6664C9F39FQ34062683-A2E2E1A1-FECE-462C-AFD6-C8C3AC9EEB79Q34262532-0435E661-325E-4D4A-869A-27803255110FQ34454042-668CE6A9-5FDF-49A2-BFA8-0660EFD69433Q34500495-E8154EB2-0AA1-407C-ADC8-46953BB3D7F7Q35914680-24212DD3-4FD7-4E57-AA72-D26602C091C3Q35987334-47FBA42D-EB1C-470B-B3A7-12EA78185845Q36030770-1CEDD325-2AF1-43CF-BC4F-FB1D77A392D2Q36095004-C45C576A-63B9-46DE-99D5-6DA7B114292FQ36632245-88328B2B-30EF-464F-BAAF-09CC83D767C4Q36816318-8CF8C81D-9ADE-43B0-A03C-946BC2495FA4Q36944047-57574B7A-AF36-4B15-9FD3-853F289159AEQ36977553-5F37A72F-C041-4322-A5EC-FA895CAE0D23Q37068082-E7CA2A0E-B5EE-4C9B-B907-D60B542D6DA9Q37339357-EB2A6F10-833D-43F7-B230-C5C331FE2086Q37377834-125EF071-ED61-4A4B-9277-E16162BC0826Q37381163-9950ACBE-865A-45C6-8030-1514A470DAA6Q37431023-BE94DFAC-5B6F-432B-862A-420843914E7AQ37435846-DCD878B7-ABE0-443C-8BE5-340E872BA1FFQ37453821-67CCBFF9-4BB0-4365-AC27-9E8F26F8AAF2Q37851738-57747588-DBD9-4E7F-844D-891C35C3C395Q37990969-CB74798F-E547-46BC-B04D-C8ADFE6E394DQ38014531-2AD64ABA-6239-402C-826C-A977F4E44501Q38722990-85C81097-120A-4B1A-A2F0-7ABA9E794463Q38875292-8155FFD5-232A-43BF-8A0F-1B23B6469B8DQ39301469-AF033144-BBDD-4074-8B14-69A82792BFC2Q39602248-A5A21747-7961-4F88-BB67-9B38BA07CCB8Q40885761-B5DA1DE7-2CDB-4634-9A80-5F6E753C3091Q47966722-5E1FAF3E-AB9B-489C-90E1-01FB4AE321E4Q54310457-D363BCDE-E1E9-4FB5-8268-50111A5C7256Q57571789-99A7BD5A-5A0D-418D-BB8A-085069F12BD4
P2860
Detection of B-RAF and N-RAS mutations in human melanoma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Detection of B-RAF and N-RAS mutations in human melanoma.
@en
type
label
Detection of B-RAF and N-RAS mutations in human melanoma.
@en
prefLabel
Detection of B-RAF and N-RAS mutations in human melanoma.
@en
P2093
P1476
Detection of B-RAF and N-RAS mutations in human melanoma.
@en
P2093
Barbara Mann
David H Gorski
Emmanuel M Gabriel
F Joseph Germino
Hyunjin J Kim
James S Goydos
Janivette Alsina
Weichung Shih
P304
P356
10.1016/J.JAMCOLLSURG.2004.10.032
P577
2005-03-01T00:00:00Z